Further US Patent Grant for Sareum's Kinase Inhibitors
Sareum (AIM: SAR),the specialist cancer drug discovery business, is pleased to announce that the U.S. Patent and Trademark Office has issued notification that a further patent has been granted for one of Sareum's key drug discovery inventions.
This patent*, which relates to compounds that inhibit or modulate the activity of kinase enzymes, forms the basis of Sareum's SKIL® drug discovery platform. The granting of this patent means that Sareum has extended its approved patent protection in the US for key elements of its SKIL platform and many of its drug discovery programmes. The Company has received similar protection in Japan and China and expects to receive it in Europe and other major markets in due course.
SKIL (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.
* Patent No. US 8,921,544
Sareum's CSO, Dr John Reader, commented: "This further grant of patent coverage for Sareum in the USA continues the strengthening of our patent portfolio, and enhances our negotiating position with potential licensing and collaboration partners".
there are a lot of people only to quick to blame people here and all it will take is one good deal to change things and it is not a matter of how as to be more a matter of when every trial and approval has to be good the AIM will not kill of every investment but sadly time takes its toll and some forget why they have shares because they brought them no on else so stop bleating like lost sheep and stop knocking the people who you invested in
I dare say its those YA Global boys again - any sign of liquidity and they dump more of the stock they get as part of last June's financing. There was 2.4million shares dumped in three quick trades leading to the markdown.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.